The objective of the current study is to investigate the safety and efficacy of linagliptin
(5mg / once daily) given for 52 weeks as add-on therapy to patients with type 2 diabetes
mellitus and insufficient glycaemic control despite diet, exercise, and treatment with one
approved antidiabetic drug.